INV-17 ROR gamma inhibitors for Oral development for Psoriasis demonstrate therapeutic treatment efficacy in a mouse Imiquimod-induced psoriasis disease model.
2017.03.03. Psoriasis treatment efficacy of an Oral INV-17 ROR gamma inhibitor in a mouse Imiquimod Psoriasis model presented at the 2017 AAD Annual Meeting in Orlando, FL
Previous
Previous
2017.09.13. Preclinical POC data in a mouse Psoriasis model following Topical treatment with small molecule INV-17 ROR gamma inhibitor presented at the 2017 EADV Annual Meeting in Geneva, Switzerland
Next
Next